The Challenge of Change - Managing Excipients Control
Colorcon
| « Previous month | Next month » |
ATMI completes expansion at US bioprocess tech plant days after citing life science business growth as an important part of its second quarter gains.
The medical unit of Becton Dickinson (BD) reported a slight increase in revenues in the third quarter driven by solid sales of diabetes products.
Marina Biotech has acquired the intellectual property for the Smarticles liposomal-based delivery system from Novosom AG.
Significant biopharm consolidation has played a key role in reshaping the drug development sector. Viq Pervaaz, senior vice president at Aon Consulting, discusses the changes and how they will impact on contract research organizations (CRO).
Consolidated sales at Hovione increased by 15 per cent to $144m (€110m) in fiscal 2009.
Mylan hopes new solid-dose packaging plant in Hungary will help it increase market share in Eastern Europe.
Cellexus has expanded its disposable bioreactor offering with a unit designed to give biomanufacturers greater flexibility in their choice of cell lines.
US testing instrument maker Mocon has moved to a bigger HQ and manufacturing centre to help it keep up with what it describes as growing demand for its range of products and services.
Oracle has introduced an integrated mass-serialisation and pedigree application to improve pharma supply chain integrity.
Colorcon will buy Indian group Pharmaceuitcal Coatings to expand both its tablet film coating business and presence in “rapidly growing” pharmaceutical market.
Research into the use of quadrupole resonance spectroscopy (QR) for non-invasive, non-destructive detection of counterfeits has been boosted by a grant.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Phage Pharmaceuticals, the USP and Nycomed.
Azelis Pharma has launched Syral starch-derived oral excipients in the UK.
Medical Technology group Becton Dickson (BD) will build a $38m warehouse facility in Four Oaks, North Carolina, according to State Governor Bev Perdue.
European drugmakers Sanofi-Aventis and GlaxoSmithKline (GSK) are rumoured to be looking at a possible acquisition of US biotechnology group Genzyme.
The US FDA has asked Ampac Fine Chemicals for a more detailed plan to fix cGMP deviations at its API plant in Rancho Cordova, California.
EU seizures of medicines suspected of infringing IP increased in 2009, with a total of almost 11.5m articles being detained.
Sensient Technologies hopes investment in pharmaceutical coating capacity will boost its pharmaceutical sector business.
Austria’s Constantia Packaging will pay Amcor €92m ($118m) for its Spanish Tobepal flexible packaging business.
Danish plans to develop its own guidelines for API audit reports have been criticised by a body that is calling for harmonisation across Europe.
Mandatory recalls of drugs posing an imminent threat to human health could be initiated by the US FDA if a bill introduced last week is passed into law.
Indian contractor Terrene Pharma has filed a DMF for hard gelatin capsules with the US FDA, signalling its intention to expand in the world’s most lucrative drug market.
The US FDA is set to make a final approval decision on the one remaining inhalable delivery insulin product, MannKind’s Afrezza, by December 29.
Reaxa has received a UK Technology Strategy Board (TSB) award to further development of cleaner catalysts for pharmaceutical manufacturing.
CROs MDCI and CDSS have partnered to expand their geographic reach and drive growth through cooperation.
Dow Wolff Cellulosics (DWC) and Colorcon say new excipient meets with growing demand for direct compression in tablet manufacturing.
Pantec Biosolutions AG has secured a CHF20m ($19m) investment to further development of its needle-free in vitro fertilisation (IVF) therapy.
A group of Irish drug firms and banks plan to set up a “global pharmaceutical centre of excellence” (COE) that they believe will create 4,800 research, development and manufacturing jobs.
Emergent BioSolutions says additional biomanufacturing space at its Baltimore, Maryland plant could help reduce expenditure through use of new timesaving manufacturing tech.
The FDA has joined with other US federal agencies to collectively research methods for predicting the toxicity of chemicals.
Australian vaccine maker CSL says new $235m plant will advance development of its portfolio of biotech cancer drugs, anti-infectives and plasma products.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including a new leader at PhRMA and KV replacing its CFO after three months in the job.
Germany’s Merck KGaA has completed its $7bn (€b5.2n) acquisition of Millipore, unveiling plans to target “high-growth, high-margin” bio-research and bio-production markets.
GSK and Pfizer’s ViiV Healthcare JV says it will make its entire drug portfolio available to generics manufacturers and 80 per cent the global HIV-infected population.
Penn Pharma and Xcelience have formed an Xcelodose-focused joint venture to meet client demand in Europe and Asia for powder-in-capsule (PIC) services.
Covering PPD and Pfizer, Sweden and Switzerland our European map-based quiz tests your knowledge of recent biopharm events against colleagues, peers and our community of readers.
M&A can help revitalize firms but failure to properly integrate the companies can create an inefficient, demoralized business. In this article, Viq Pervaaz, senior vice president at Aon Consulting, takes a look at M&A processes, pitfalls and keys to success.
Encap has announced its DuoCap capsule delivery system has been granted US and European patents that strengthen the firm’s portfolio in the delivery of pharmaceutical active agents that require controlled release.
Mylan are to acquire Bioniche Pharma’s global injectable pharmaceuticals business for $550m (€430m) in a deal that gives Mylan a significant foothold in meeting product and therapeutic gaps in the US injectables market.
Bosch Packaging has identified Asia as a key engine for future growth as its chief announced its international presence had helped the firm to “stand our ground in the global market place” during a tough 2009.
Gerresheimer reports its second quarter profit from operations has grown year-on-year from €11.8m ($15.1m) to €24.8m.
ATMI Lifesciences has introduced 2D and 3D single-use bioprocess vessels (BPV) which reduce risk and cut costs.
The Institute for OneWorld Health (iOWH) has moved one step closer to supplying a key component of a malaria treatment on an industrial scale as it revealed details of its latest activities to bring the ingredient to regions in short supply.
Research has been initiated into the prediction of process performance before scale up to help increase yield and efficiency while cutting costs.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at GSK, KV Pharmaceutical, ParagonRx, West, Novavax and Unilife.
The LSD of the Philippine Food and Drug Administration (FDA) has taken a step towards raising standards by gaining ISO/IEC 17025:2005 accreditation.
A new study believes vaccine manufacturers from developing countries may be able to produce a HPV vaccine at a lower cost without infringing on the numerous patents drug makers have taken out on the vaccine technology.
Prosonix has entered into an agreement with Trimel Biopharma, in which both companies will combine their respective technologies to deliver improved inhalation performance for respiratory medicines.
Merck & Co is to close or sell eight manufacturing plants and a further eight R&D laboratories as part of efforts to cuts its workforce by 15 per cent.
Sandoz is conducting a UK patient level recall of certain batches of Temozolomide capsules after they were found to be splitting and leaking powder.
Brazilian generics manufacturer Eurofarma has acquired Uruguay counterpart Laboratorios Gautier, further expanding its reach across Latin America.
SurModics has licensed certain elements of its biodegradable polymer implant technology to Clinuvel for use treating sun-induced skin disorders.
Genzyme has entered into an expanded fill and finish manufacturing deal with Hospira as it works to move operations out of its Allston Landing plant.
Millipore is targeting protein manufacturers with a new chromatography resin that, the firm claims, offers flexibility and high throughput with a small manufacturing footprint.
Sagent Pharmaceuticals’ heparin sodium injection, USP, which uses packaging and labelling safety features, has been approved by the US Food and Drug Administration (FDA).
China-based companies’ desire to enter the international vaccine market represents an “important opportunity” for Canada, according to a CIC paper.
Pharming has entered into a toll manufacturing agreement with Sanofi Chemie to boost capacity, secure supply and lower costs of Ruconest (conestat alfa).
The rapidly evolving Asian drug manufacturing sector represents both an opportunity and a challenge for the fine chemicals and molecules industry, according to SAFC president Gilles Cottier.
The potential of microbial cells as producers of nanomaterials has been underestimated and further research is needed to improve the situation, according to an academic.
EyeTechCare has raised €7.5m ($9.4m) to support development of its non-invasive glaucoma treatment.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Elan, Inspire Pharmaceuticals, BioVex and Lux Biosciences.
UK API maker Aesica has bought formulation firm R5 Pharmaceuticals, continuing the expansion strategy it has employed over the last few years.
Chemicals manufacturer BASF reorganises Swiss business to cut active pharmaceutical ingredient (API) manufacturing site complexity and simplify process operations.
Converters and manufacturers will be able to measure the real-life performance of packaging barrier products with greater speed and accuracy thanks to an enhanced water vapour transmission rate (WVTR) instrument, said Mocon Inc.
Eli Lilly is moving into the enzyme replacement therapy (ERT) market with the acquisition of US biotechnology firm Alnara Pharmaceuticals.
Rumour has it that French drug giant Sanofi Aventis is planning to make a $20bn (€16bn) acquisition in the US with speculation that biotechs like Allergan, Biogen Idec and Genzyme are among the targets.
Aptuit is to acquire GSK’s Italian R&D centre, take on its 500 employees and become part of the big pharma’s CRO network.
Abbott Laboratories has confirmed it is considering the sale of the vaccines unit it gained with the €4.5bn ($6.2bn) acquisition of Solvay Pharmaceuticals in February .
GlaxoSmithKline (GSK) and the Singapore EDB are to fund eight research projects into green and sustainable production of pharmaceuticals and fine chemicals.
| « Previous month | Next month » |